Two human melanoma xenografts with different metastatic capacity and glycosaminoglycan pattern

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Two human melanoma xenografts were compared with respect to their in vivo growth and metastatic potentials as well as glycosaminoglycan patterns. The less differentiated HT 168 tumor showed faster growth at primary sites and a more pronounced capacity for metastasis into the liver. Although chondroitin sulfate was the dominant glycosaminoglycan subtype in both tumors, the more invasive xenograft had a higher heparan sulfate/chondroitin sulfate (HS/CS) ratio. We suggest that tumor progression is influenced by this ratio in this human melanoma system.

Original languageEnglish
Pages (from-to)554-557
Number of pages4
JournalJournal of Cancer Research and Clinical Oncology
Volume115
Issue number6
DOIs
Publication statusPublished - Nov 1989

Fingerprint

Glycosaminoglycans
Heterografts
Melanoma
Chondroitin Sulfates
Neoplasms
Heparitin Sulfate
Growth
Neoplasm Metastasis
Liver

Keywords

  • Glycosaminoglycan
  • Human melanoma
  • Metastasis
  • Xenograft

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{adb6201959b2450dba163083aa654a52,
title = "Two human melanoma xenografts with different metastatic capacity and glycosaminoglycan pattern",
abstract = "Two human melanoma xenografts were compared with respect to their in vivo growth and metastatic potentials as well as glycosaminoglycan patterns. The less differentiated HT 168 tumor showed faster growth at primary sites and a more pronounced capacity for metastasis into the liver. Although chondroitin sulfate was the dominant glycosaminoglycan subtype in both tumors, the more invasive xenograft had a higher heparan sulfate/chondroitin sulfate (HS/CS) ratio. We suggest that tumor progression is influenced by this ratio in this human melanoma system.",
keywords = "Glycosaminoglycan, Human melanoma, Metastasis, Xenograft",
author = "J. T{\'i}m{\'a}r and I. Kovalszky and S. Paku and K. Lapis and L. K{\'o}pper",
year = "1989",
month = "11",
doi = "10.1007/BF00391357",
language = "English",
volume = "115",
pages = "554--557",
journal = "Zeitschrift fur Krebsforschung und Klinische Onkologie",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Two human melanoma xenografts with different metastatic capacity and glycosaminoglycan pattern

AU - Tímár, J.

AU - Kovalszky, I.

AU - Paku, S.

AU - Lapis, K.

AU - Kópper, L.

PY - 1989/11

Y1 - 1989/11

N2 - Two human melanoma xenografts were compared with respect to their in vivo growth and metastatic potentials as well as glycosaminoglycan patterns. The less differentiated HT 168 tumor showed faster growth at primary sites and a more pronounced capacity for metastasis into the liver. Although chondroitin sulfate was the dominant glycosaminoglycan subtype in both tumors, the more invasive xenograft had a higher heparan sulfate/chondroitin sulfate (HS/CS) ratio. We suggest that tumor progression is influenced by this ratio in this human melanoma system.

AB - Two human melanoma xenografts were compared with respect to their in vivo growth and metastatic potentials as well as glycosaminoglycan patterns. The less differentiated HT 168 tumor showed faster growth at primary sites and a more pronounced capacity for metastasis into the liver. Although chondroitin sulfate was the dominant glycosaminoglycan subtype in both tumors, the more invasive xenograft had a higher heparan sulfate/chondroitin sulfate (HS/CS) ratio. We suggest that tumor progression is influenced by this ratio in this human melanoma system.

KW - Glycosaminoglycan

KW - Human melanoma

KW - Metastasis

KW - Xenograft

UR - http://www.scopus.com/inward/record.url?scp=0024810963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024810963&partnerID=8YFLogxK

U2 - 10.1007/BF00391357

DO - 10.1007/BF00391357

M3 - Article

C2 - 2606930

AN - SCOPUS:0024810963

VL - 115

SP - 554

EP - 557

JO - Zeitschrift fur Krebsforschung und Klinische Onkologie

JF - Zeitschrift fur Krebsforschung und Klinische Onkologie

SN - 0171-5216

IS - 6

ER -